Association of plasma advanced glycation end‐products and their soluble receptor with type 2 diabetes among Chinese adults

Abstract

AbstractAimsPopulation‐based evidence regarding circulating advanced glycation end‐products (AGEs) and the risk of type 2 diabetes (T2D) is conflicting and insufficient. We aimed to examine the association of plasma AGEs and plasma soluble receptors for AGEs (sRAGE) with T2D.Materials and MethodsWe conducted a hospital‐based case–control study including 1072 pairs (53.9 ± 9.7 years, 56.0% male) of newly diagnosed T2D and age‐ and sex‐matched controls. We further performed a nested case–control study within an ongoing prospective cohort consisting of 127 incident T2D cases and 381 well‐matched controls (62.2 ± 5.1 years, 71.7% male). Plasma AGEs were detected using liquid chromatography–tandem mass spectrometry, and plasma sRAGE was measured by enzyme‐linked immunosorbent assay. Conditional logistic regression was used to evaluate the association of plasma AGEs and sRAGE concentrations with T2D.ResultsHigher plasma AGEs and lower sRAGE concentrations were associated with higher odds of T2D. The multivariable‐adjusted odds ratios of T2D comparing the highest with the lowest quartile levels were 3.28 (95% CI: 2.14, 5.02) for plasma AGEs and 0.25 (95% CI: 0.16, 0.39) for plasma sRAGE. Participants in the highest quartile of plasma AGEs and the lowest quartile of sRAGE concentrations had the greatest odds of T2D. The positive association of AGEs and inverse association of sRAGE with T2D risk was confirmed in the replication‐nested case–control study.ConclusionsIncreased circulating AGEs and decreased sRAGE concentrations were associated with elevated T2D risk. Our findings may have implications for the strategies of T2D prevention and management.